Sorafenib improves the postoperative effect of early stage renal cell carcinoma

Abstract

Sorafenib was examined to determine whether it improves postoperative effects during early stage renal cell carcinoma (RCC). A total of 133 patients with early renal clear cell carcinoma (T1-2N0M0) with surgical indications were continuously selected. The patients were divided into 3 groups according to different treatments, including the surgery alone… (More)
DOI: 10.3892/ol.2016.5243

Topics

4 Figures and Tables

Slides referencing similar topics